中度至重度斑块状银屑病患者登记 (PURE)
加拿大和拉丁美洲 (LACan) 中度至重度慢性斑块状银屑病患者登记
The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.
研究概览
地位
地位
干预/治疗
干预/治疗
详细说明
PURE is a multi-national, prospective, observational cohort study of patients with moderate to severe chronic plaque psoriasis aimed at assessing the real-world safety and effectiveness of secukinumab and other indicated therapies. The study will enroll patients for whom, prior to and independent of study enrollment, the treating physician has decided to treat with secukinumab, or one of the other indicated therapies regimens approved for the management of moderate to severe chronic plaque psoriasis.
Two study cohorts will be defined by patients treated with secukinumab (Cohort 1), and patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy; Cohort 2). Each investigator will recruit approximately the same number of patients in each treatment arm. 2,500 patients (1,250 patients in each cohort) will be followed over a period of 5 years from the Baseline assessment (Visit 1).
研究类型
研究类型
注册 (实际的)
注册
联系人和位置
学习地点
-
-
Alberta
-
Edmonton、Alberta、加拿大、T6G 1C3
- Novartis Investigative Site
-
-
British Columbia
-
Nanaimo、British Columbia、加拿大、V9T 1W1
- Novartis Investigative Site
-
Surrey、British Columbia、加拿大、V3R 6A7
- Novartis Investigative Site
-
Surrey、British Columbia、加拿大、V3V 0C6
- Novartis Investigative Site
-
Vancouver、British Columbia、加拿大、V5Z 1M9
- Novartis Investigative Site
-
Victoria、British Columbia、加拿大、V8V 3M9
- Novartis Investigative Site
-
-
Manitoba
-
Brandon、Manitoba、加拿大、R7A 0L5
- Novartis Investigative Site
-
Winnepeg、Manitoba、加拿大、R3M 1Z9
- Novartis Investigative Site
-
Winnipeg、Manitoba、加拿大、R3C 0N2
- Novartis Investigative Site
-
-
New Brunswick
-
Fredericton、New Brunswick、加拿大、E3B 1G9
- Novartis Investigative Site
-
Rothesay、New Brunswick、加拿大、E2E 5N4
- Novartis Investigative Site
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、加拿大、A1A 4Y3
- Novartis Investigative Site
-
St. John's、Newfoundland and Labrador、加拿大、A1C 2H5
- Novartis Investigative Site
-
St. John's、Newfoundland and Labrador、加拿大、A1E 1V4
- Novartis Investigative Site
-
-
Nova Scotia
-
Kentville、Nova Scotia、加拿大、B4N 4K9
- Novartis Investigative Site
-
-
Ontario
-
Cobourg、Ontario、加拿大、K9A 4J9
- Novartis Investigative Site
-
Hamilton、Ontario、加拿大、L8N 3Z5
- Novartis Investigative Site
-
Hamilton、Ontario、加拿大、L9B 1K5
- Novartis Investigative Site
-
London、Ontario、加拿大、N6H 5L5
- Novartis Investigative Site
-
London、Ontario、加拿大、N6A 2C2
- Novartis Investigative Site
-
London、Ontario、加拿大、N6A 3H7
- Novartis Investigative Site
-
Markham、Ontario、加拿大、L3P 1X3
- Novartis Investigative Site
-
Mississauga、Ontario、加拿大、L4W 0C2
- Novartis Investigative Site
-
Mississauga、Ontario、加拿大、L4Y 4C5
- Novartis Investigative Site
-
Nepean、Ontario、加拿大、K2G 6E2
- Novartis Investigative Site
-
Niagara Falls、Ontario、加拿大、L2H 1H5
- Novartis Investigative Site
-
North York、Ontario、加拿大、M3B 3N1
- Novartis Investigative Site
-
Peterborough、Ontario、加拿大、K9J 5K2
- Novartis Investigative Site
-
Richmond Hill、Ontario、加拿大、L4C 9M7
- Novartis Investigative Site
-
Toronto、Ontario、加拿大、M2M 4J5
- Novartis Investigative Site
-
Toronto、Ontario、加拿大、M3H 5Y8
- Novartis Investigative Site
-
Toronto、Ontario、加拿大、M4W 2N2
- Novartis Investigative Site
-
Waterloo、Ontario、加拿大、N2J 1C4
- Novartis Investigative Site
-
Waterloo、Ontario、加拿大、N1H 1B1
- Novartis Investigative Site
-
-
Quebec
-
Laval、Quebec、加拿大、H7N 6L2
- Novartis Investigative Site
-
Montreal、Quebec、加拿大、H3H 1V4
- Novartis Investigative Site
-
Montreal、Quebec、加拿大、H2X 1R9
- Novartis Investigative Site
-
-
-
-
-
Guatemala City、危地马拉、01011
- Novartis Investigative Site
-
-
-
-
Estado de Baja California
-
Mexicali、Estado de Baja California、墨西哥、21100
- Novartis Investigative Site
-
-
Jalisco
-
Guadalajara、Jalisco、墨西哥、44638
- Novartis Investigative Site
-
-
Mexico
-
Guadalajara Jalisco、Mexico、墨西哥、44610
- Novartis Investigative Site
-
-
Mexico City
-
Del Tlalpan、Mexico City、墨西哥、14389
- Novartis Investigative Site
-
-
Nuevo León
-
San Pedro G G、Nuevo León、墨西哥、66220
- Novartis Investigative Site
-
-
State of Mexico
-
Toluca、State of Mexico、墨西哥、50120
- Novartis Investigative Site
-
-
-
-
-
Santiago de los Caballeros、多明尼加共和国、51000
- Novartis Investigative Site
-
Santo Domingo、多明尼加共和国、10103
- Novartis Investigative Site
-
-
-
-
-
Panama City、巴拿马、0831
- Novartis Investigative Site
-
-
-
-
-
Caba、阿根廷、C1425BEA
- Novartis Investigative Site
-
-
Buenos Aires
-
Adrogué、Buenos Aires、阿根廷、B1846DTL
- Novartis Investigative Site
-
CABA、Buenos Aires、阿根廷、C1181ACH
- Novartis Investigative Site
-
Caba、Buenos Aires、阿根廷、C1024AAO
- Novartis Investigative Site
-
-
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patient with moderate to severe plaque psoriasis
描述
Inclusion Criteria:
- - Patients able to give written informed consent
- - Patients at least 18 years of age at time of informed consent signature
- - Confirmed diagnosis of chronic moderate to severe chronic plaque-type psoriasis diagnosed by a specialist and presence of moderate to severe psoriasis symptoms according to physician's clinical judgment at the time of recruitment.
- - Patients initiating a treatment for psoriasis as per regional policy. This will include secukinumab, other biologics, systemic treatments, and phototherapy. Decision to treat with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study.
- - Treatments prescribed in accordance to the product monograph and regional regulatory and reimbursement policies
- - Patients able to understand and communicate with the investigator and comply with the requirements of the study.
Exclusion Criteria:
- - Unwillingness or inability to comply with the study requirements
- - Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
团体/队列数
队列和干预
团体/队列团体/队列 |
干预/治疗干预/治疗 |
|---|---|
|
Secikinumab
Patients treated with secukinumab |
其他名称:
|
|
Approved standard of care
Patients treated with other indicated therapies (systemic, phototherapy, or biologic therapy) |
其他名称:
|
研究衡量的是什么?
主要结果指标
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
大体时间:Change from Baseline through month 60
|
Incidence of all adverse events in the study cohorts as measured by:
|
Change from Baseline through month 60
|
次要结果测量
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
工作效率和活动障碍 (WPAI) 分数的平均变化
大体时间:从基线到第 60 个月的变化
|
从基线到第 60 个月的变化
|
|
|
医院焦虑和抑郁量表 (HADS) 评分的平均变化
大体时间:从基线到第 60 个月的变化
|
从基线到第 60 个月的变化
|
|
|
银屑病症状日记 (PSD) 评分的平均变化
大体时间:从基线到第 60 个月的变化
|
从基线到第 60 个月的变化
|
|
|
治疗满意度量表 (TSS) 分数的平均变化
大体时间:从基线到第 60 个月的变化
|
从基线到第 60 个月的变化
|
|
|
皮肤科生活质量指数 (DLQI) 得分的平均变化
大体时间:从基线到第 60 个月的变化
|
从基线到第 60 个月的变化
|
|
|
银屑病流行病学筛查工具 (PEST) 评分的平均变化
大体时间:从基线到第 60 个月的变化
|
从基线到第 60 个月的变化
|
|
|
与银屑病相关的直接和间接成本的平均变化
大体时间:从基线到第 60 个月的变化
|
从基线到第 60 个月的变化
|
|
|
Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response
大体时间:Change from Baseline through month 60
|
PASI: Combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section(head: 0.1, arms: 0.2 body: 0.3 legs: 0.4) |
Change from Baseline through month 60
|
合作者和调查者
出版物和有用的链接
一般刊物
- Papp KA, Gooderham M, Beecker J, Lynde CW, Delorme I, Dei-Cas I, Albrecht L, Rampakakis E, Sampalis JS, Vieira A, Hussein S, Chambenoit O, Rihakova L. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America. BMC Dermatol. 2019 Jun 21;19(1):9. doi: 10.1186/s12895-019-0087-3.
- Papp KA, Gooderham M, Dei-Cas I, LopezTello A, Garcia-Rodriguez JC, Taveras CY, Rousselin AH, Lavieri A, Maiolino M, Quintero DGV, Rihakova L, Salibe M, Pertuz W. Effectiveness and Safety of Secukinumab in Latin American Patients with Moderate to Severe Plaque Psoriasis: PURE Registry 12-Month Data. Dermatol Ther (Heidelb). 2023 Jan;13(1):269-283. doi: 10.1007/s13555-022-00849-0. Epub 2022 Dec 10.
- Beecker J, Albrecht L, Dei-Cas I, Gooderham M, Lynde C, Papp KA, Keown P, Vieira A, Farag MS, Maguin M, Zappitelli T, Helliwell PS. Longitudinal Performance of the Psoriasis Epidemiology Screening Tool (PEST) in Canada and Latin America: Results from the Prospective, Observational, 5-Year PURE Registry. Dermatol Ther (Heidelb). 2026 Aug;16(8):4097-4115. doi: 10.1007/s13555-026-01826-7. Epub 2026 Jul 21.
研究记录日期
研究主要日期
学习开始 (实际的)
学习开始
初级完成 (实际的)
初级完成
研究完成 (实际的)
研究完成
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (估计的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
其他研究编号
- CAIN457ACA02
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.